Biorestorative Therapies Inc. (BRTX)
Summary
BRTX Chart
What Makes Biorestorative Therapies (BRTX) a New Buy Stock
Biorestorative Therapies (BRTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates
Biorestorative Therapies, Inc. (BRTX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.56 per share a year ago.
Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing
Biorestorative Therapies (BRTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Biorestorative Therapies Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Kevin Bresler TD Waterhouse Canada Inc. | 3 | $5.26 | $1.05 | -$4.21 | -80.04% |
| RFL Rossby Financial LLC Rossby Financial LLC | 11 | $19.25 | $3.96 | -$15.29 | -79.43% |
Biorestorative Therapies Inc. (BRTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biorestorative Therapies Inc. ever had a stock split?
Biorestorative Therapies Inc. Profile
| Biotechnology Industry | Healthcare Sector | Lance Alstodt CEO | NASDAQ (CM) Exchange | 090655606 CUSIP |
| US Country | 14 Employees | - Last Dividend | 7 Jul 2015 Last Split | - IPO Date |
Overview
BioRestorative Therapies, Inc. specializes in the development of therapeutic products and medical therapies that primarily utilize adult stem cells. The company’s research and development efforts are largely focused on addressing disorders related to the disc/spine and metabolic diseases. BioRestorative Therapies, Inc. collaborates with notable entities in the medical field, including Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania, to enhance its research and development capabilities. Originally known as Stem Cell Assurance, Inc., the company rebranded to its current name in August 2011 and operates out of Melville, New York.
Products and Services
BRTX-100
BRTX-100 is BioRestorative Therapies’ leading cell therapy candidate, designed for the non-surgical treatment of painful lumbosacral disc disorders. This therapeutic approach employs autologous cultured mesenchymal stem cells harvested from the patient’s own bone marrow. BRTX-100 can serve as an independent, non-surgical option or complement surgical procedures, offering hope for individuals suffering from chronic disc-related pain.
ThermoStem®
ThermoStem® represents a pioneering cell-based therapy targeting obesity and metabolic disorders. The treatment uses stem cells derived from brown adipose tissue to foster the generation of brown adipose tissue in the patient. By focusing on the metabolic functions of brown adipose tissue, ThermoStem® aims to offer a novel solution for tackling obesity and its associated metabolic complications.
Investigational Curved Needle Device
In its quest to enhance the delivery of cell therapies and other therapeutic products, BioRestorative Therapies has also developed an investigational curved needle device. This specialized tool is designed to accurately deliver cells and therapeutic agents to targeted areas within the spine, discs, and other parts of the body, enhancing the precision of treatments.
